Long-Term Safety and Efficacy of Pitavastatin in Patients With Acute Myocardial Infarction (from the Livalo Acute Myocardial Infarction Study [LAMIS])

Pitavastatin is a potent lipophilic statin and may play an important role in acute myocardial infarction (AMI) but there have been limited data on the safety and efficacy of pitavastatin in AMI. This study consisted of 1,039 consecutive patients with AMI (74.0% men, mean age 61.4 ± 12.6 years) who p...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2011-12, Vol.108 (11), p.1530-1535
Main Authors: Suh, Soon Yong, MD, Rha, Seung-Woon, MD, Ahn, Tae Hoon, MD, Shin, Eak Kyun, MD, Choi, Cheol Ung, MD, Oh, Dong Joo, MD, Bae, Jang-Ho, MD, Hur, Seung-Ho, MD, Yoon, Kyung Ho, MD, Oh, Seok-Kyu, MD, Kim, Jong Hyun, MD, Kim, Sang Wook, MD, Chae, In Ho, MD, Kim, Kee-Sik, MD, Hong, Young Joon, MD, Jeong, Myung Ho, MD
Format: Article
Language:English
Subjects:
Angioplasty
Biological and medical sciences
Cardiology
Cardiology. Vascular system
Cardiovascular
Cause of Death - trends
Cholesterol, LDL - blood
Coronary heart disease
Drug dosages
Electrocardiography
Female
Follow-Up Studies
Heart
Heart attacks
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Incidence
Male
Medical sciences
Middle Aged
Myocardial Infarction - blood
Myocardial Infarction - drug therapy
Myocardial Infarction - epidemiology
Myocarditis. Cardiomyopathies
Prospective Studies
Quinolines - administration & dosage
Quinolines - therapeutic use
Republic of Korea - epidemiology
Side effects
Statins
Survival Rate - trends
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pitavastatin is a potent lipophilic statin and may play an important role in acute myocardial infarction (AMI) but there have been limited data on the safety and efficacy of pitavastatin in AMI. This study consisted of 1,039 consecutive patients with AMI (74.0% men, mean age 61.4 ± 12.6 years) who presented in 10 major percutaneous coronary intervention centers in Korea from February 2007 through September 2009. Pitavastatin 2 mg/day was routinely administered in patients with AMI from time of presentation. We investigated changes of lipid profiles, biochemical markers, adverse events, and clinical outcomes up to 12 months. During the study 318 events overall occurred in 220 patients (21.2%) who reported ≥1 treatment emergent adverse event, although 20 events in 14 patients (1.4%) were treatment-related adverse events. Low-density lipoprotein (LDL) cholesterol percent change was −25.6% and LDL cholesterol target attainment was 70.5% at 12-month follow-up. Levels of creatinine phosphokinase, serum glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, and high-sensitivity C-reactive protein decreased significantly during the first 1 month of pitavastatin treatment and were sustained to 12-month follow-up. Major adverse cardiac events occurred in 66 patients (7.3%). All-cause deaths occurred in 32 patients (3.5%) including 19 (2.1%) cardiac deaths and recurrent MIs occurred in 14 (1.6%) and target lesion revascularizations in 42 (4.7%). In conclusion, administration of pitavastatin 2 mg/day in patients with AMI showed 70.5% LDL cholesterol target attainment with good tolerance and was associated with favorable clinical outcomes up to 12 months.
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2011.07.009